Introduction
'Big data' is defined by '7 V's': volume (most frequently cited 1 ), velocity, veracity, variety, volatility, validity and value. In healthcare, 'big data' is associated with a step-change in the way information is gathered, analysed and used to facilitate disease management and prevention. With greater electronic data capture, there is enthusiasm for increased safety, efficiency and effectiveness in health and social care through, for example, machine learning and other forms of artificial intelligence (AI). However, factors maintaining and widening the gap between the promise and the reality need to be addressed.
Can 'big' be evidence-based?
Current best practice has its foundation in evidence-based healthcare, with growth in publications, but poorly managed scientific insights, poor recording of care and poor use of evidence. 2 Big data could improve the status quo and support learning health systems (LHS). 3 Computational methods can contribute to evidence management with automation of literature searching, critical appraisal and guidelines. 4 5 Similarly, big data already contribute to aetiological, diagnostic, prognostic and therapeutic research, from -omics to electronic health records (EHR) trials. 6 Critics emphasise lack of quality and validation of routinely collected clinical data, and risk of bias in observational studies, where scale cannot compensate for poor design. 7 Conversely, data-driven approaches could transform a predominantly retrospective into a prospective or real-time paradigm, across disease boundaries. Infrastructure and analytic tools are necessary but often poorly understood and underdeveloped. Automated extraction of necessary data fields in pseudonymised/anonymised format into curated warehouses is required with robust metadata catalogues and understanding of clinical context. To be available at the point-of-care for clinicians, data will have to be extracted, cleaned and processed promptly.
Preventing excesses and addressing deficiencies
Medicine grapples with conflicting challenges of overdiagnosis and overtreatment as well as underdiagnosis and undertreatment. Widening inequalities also manifest across many health systems, despite improving medications and technologies. Efforts to optimise healthcare delivery have culminated in 'right care', 8 which may be facilitated by big data methods and outputs. Decision aids could help clinicians to optimise patient management, supported by large-scale EHR data. For example, among individuals who meet 'appropriateness of use criteria' (AUC) for diagnostic coronary angiography, only 52.9% have obstructive coronary disease. 9 Similarly, among elective surgery patients, routine tests of blood coagulation are unnecessary in over 94% of cases, with implications for cost and false positives. 10 It is plausible that AUC for tests could be continuously evaluated using EHR, quality improvement initiatives and new trials. In this way, 'an ideal system would be evidence-based, use uniform and comprehensive clinical data, provide point-ofcare decision support and aim to improve quality by reducing overuse and underuse' . 11 The medical 'Internet of Things' describes the growing number of apps and devices which, through big data analytics, are linking patients and health professionals, 12 for example, to tackle underdiagnosis in screening and diagnosis of atrial fibrillation, although proper evaluation is required. 13 Similarly, AI, the mimicking of human cognition by computers in the broadest sense, 14 could change data use, analysis and interpretation in radiology, pathology, oncology and several other specialties. 15 For example, AI may predict the grade and stage of lung cancer better than pathologists, but there is a paucity of well-designed studies of diagnostic accuracy, effectiveness and cost-effectiveness which can guide implementation. 16 A barrier to adoption may stem from fear of job loss and concerns around accountability, but people may be freed to work on the aspects which only humans can conduct. 15 Machine learning, one subtype of AI where computers use data to 'learn for themselves', has promise, particularly in overcoming overdiagnosis and underdiagnosis, 17 with advantages of increased efficiency, reproducibility and scalability. These benefits are illustrated by the application of 'deep learning', 14 a subset of machine learning which imitates neural networks that simulate human decision-making, in the detection of diabetic retinopathy. 18 Risk prediction is of direct relevance in the era of personalised medicine. AI may aid in the prediction of real-time risk and in visualisation and communication of those risks. Risk scores can be automated within EHRs and multiple risk scores may be deployed in the same patient simultaneously, whether in primary care or intensive care. Moreover, risk prediction can be incorporated
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into data-driven management such as personalised radiotherapy for prostate cancer. However, there are only a handful of exemplars [19] [20] [21] and models that appear efficacious are yet to be applied. 22 23 As Wachter says, there is currently 'more promise than reality' and more hype than evidence. For example, AI is currently receiving much attention, but before widespread adoption, not only is evidence required; the pace and scale at which the research is conducted must keep up, that is, big data methods are required in evidence generation. 24 Moreover, there are primary research barriers related to implementing AI and machine learning into medicine, including: appropriate and secure access to patient data; platforms to collate personal and healthcare data and linkage required to develop the models; missing, incomplete and unvalidated data 25 or development of interfaces to place predictive algorithms within EHR. There are currently no services or companies dealing with general AI applicable to any healthcare problem, and whether ethical, academic or clinical, many questions remain before it can be widely implemented.
There are scenarios where big data and associated issues are compounding rather than solving problems. For example, directto-consumer genetic testing cannot yet provide genetic information which is useful to patients or clinicians for most complex diseases and may create more anxiety than health. Moreover, lack of integration of such services into disease management pathways may lead to high costs, confusion and inappropriate use of resources. The rise in patient use of wearables is currently not related with improved patient outcomes and may increase pressures on health services, 26 thus adding to overdiagnosis and overtreatment. Inattention to 'digital divides' may worsen health inequalities.
Big data and AI all need to be used more intelligently for the individual and the health system. There is a trend towards piecemeal use of big data, which may partly be due to patchy availability of EHR and digital technologies across the NHS or patchy infrastructure for harnessing these data. The direction of travel should be throughout a patient pathway if use is to become widespread or universal. This will require appropriate, secure, linked infrastructure that can collate, link, protect, anonymise and present data to the analyst for research, with capacity to be implemented back into the healthcare setting.
Learning healthcare systems
Health informatics describes the best use, although promise, of (big) data to improve health at the individual and population level, healthcare and biomedical research. Recognition of big data in healthcare has led to many related terms/disciplines, including 'digital health', 'digital medicine', 'precision medicine' and 'personalised medicine', which overlap and interconnect with different branches of informatics (figure 1), but may confuse discussions. Taken collectively, health informatics would support a 'learning healthcare system', a framework proposed by the National Institute of Medicine in 2006 to capture the possibility of data from science, evidence and care feeding into one another in a 'virtuous' cycle 2 (figure 2). In his review, Wachter's comments are timely and far-sighted:
'In particular, the data processing, analytics, and informatics research workforce must not be forgotten, particularly since the UK has an enormous opportunity to bring the promise of big data to life. Working through ambitious entities such as the Farr Institute, the UK could be the first nation to take data science to scale and build a truly national learning health system' . 27 However, 'high-level' terminology stifles operationalisation. Many consider the LHS to be a 'platform' of infrastructure, human resources, software and other inter-related components and 'learning health cycles' to describe the science-evidence-care relationship. Regardless, the wastage throughout the pathway from science through evidence to delivery of care is matched by strains on resources in every sector, from human and infrastructural to financial and managerial. Big data methods can aid in organisation of healthcare and public health services as well as research, education and training, but at least five major paradigm shifts are required at system level. First, research and 'service' remain two parallel and relatively unconnected activities in the NHS, despite the work of NIHR and other funders to create a research-active clinical environment throughout the NHS. An important consequence is underperformance by many hospitals in terms of research. Lack of academic activity in hospitals was correlated with poor quality care in the review of underperforming hospitals conducted by Bruce Keogh 28 and was also highlighted by the Francis report. 29 The long timescale from research to impact as well as perceived and real gaps in translational research which truly changes acute care design and delivery are also barriers to research-driven care. In LHS, the provenance of data at the point-of-care encourages patient-centred research and patient-centred clinical care at the same time. On the other hand, the overall possibilities of precision medicine, whether in terms of diagnostics or therapeutics, are likely to be tested and used to their full potential in a patient-centred and data-centred environment, rather than a researcher-centric model. Second, quality improvement and audit have been generally viewed as separate to clinical research and the overlap between the two is suboptimally managed. LHS can make research scaleable and quality improvement a real-time activity. Issues such as workforce planning and predicting bed capacity are examples of particular needs where reframing as research questions may be of mutual benefit to clinicians and academics. Audit at scale could be continuous and go beyond government performance targets. There would be implications for development of the optimal metrics for patient outcomes, monitoring of burden of disease and service need, optimisation of care pathways as well as design and implementation of EHR-based trials to test service-level interventions.
Third, the capacity in health informatics among clinicians and non-clinicians is a rate-limiting step. Undergraduate and postgraduate curricula are currently largely ignoring the impact of big data on healthcare delivery, and therefore the future workforce may not be adequately prepared for data-driven healthcare. Leadership, participation and long-term vision at the national and local level are required from both academia (eg, Farr Institute of Health Informatics Research and the newly formed Health Data Research UK, independent health informatics researchers) and the NHS (eg, the Chief Clinical Informatics Officer, CCIO, network) to ensure that the rich and overlapping tapestry of quality improvement, implementation science, translational research and audit can be realised through LHS. A true LHS will require marriage of both the 'technical' (health information technology, eg, EHR) and the 'cultural' (digital health, eg, application of machine learning to medical decision-making). Within the NHS, extra efforts to support cocreation of capacity between academic and NHS sectors will be critical to keep up with University-owned hospitals internationally.
Fourth, the trust of patients and the public in the use of their data is central to developing a LHS where routine health data are optimally used. There have been historic challenges in developing largescale IT programmes in the NHS, whether Connecting for Health, or more recently, care. data, and lack of public trust in secondary use of data played a significant role. 30 Currently, Google DeepMind is working with the Royal Free Hospitals NHS Trust to develop risk prediction tools for acute kidney injury, but there have been concerns from regulatory bodies, clinicians and public regarding ethical and data security implications for this research model. A new framework for public understanding of science and trust, with involvement and cocreation at the centre, is required to make sure that these concerns are allayed before implementation so that research, innovation and care delivery are not prevented.
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Figure 2
Learning health systems and the role of biomedical informatics. 
Box 1 Barriers to learning health systems in the NHS
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Fifth, investment and engagement from patient-facing healthcare professionals (HCP) is essential for maximising LHS. Assessment of data can only be as good as the data used. Continuous feedback and improvement in how data are recorded, captured and standardised is necessary to ensure that the results of assessments provide the most pertinent information for continuous improvement. This will only come from sharing evaluations with HCP and discussing where, how and why inconsistencies and missing data persist and empowering HCP to take responsibility for continuous improvement in both healthcare provision and the recording of that provision.
These five and other barriers to LHS implementation in the NHS are highlighted in box 1. Scale-up is limited by a lack of examples of LHS in the published literature and therefore, publication, education and dissemination regarding successful projects are crucial, especially from within the NHS (box 2), rather than trying to emulate examples from other health systems which may not be completely transferable or relevant to the NHS and the UK. The costs of not implementing LHS in terms of human resources, patient safety and patient-centred outcomes have not been quantified in existing research and represent a powerful tool for engaging and convincing policymakers.
Conclusion
The learning health system is a natural progression if the full potential of the wealth of big data throughout the health sector is to be realised. Clinicians, academics, citizens and private sector can align to develop a patient-centred, data-driven model of care but multiple barriers exist in the NHS at present, including infrastructure, workforce, training and culture. Trust and evidence will be important levers for patients, public and health professionals and need be addressed urgently, along with the other barriers in the NHS. Without the learning health system approach, big data are likely to remain an entity used in discrete projects rather than across the NHS.
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Box 2 Examples of real world opportunities for learning healthcare systems in the NHS
The 100 000 Genomes Project Genomics England are sequencing 100 000 genomes from 70 000 people with a rare disease, plus their families, as well as patients with cancer. A new genomic medicine service for the NHS is being delivered via this project. https://www. genomicsengland. co. uk/ the-100000-genomesproject/ Connected Care in Berkshire Using Graphnet's CareCentric software, 17 health and social care organisations across Berkshire will share the care records of 855 000 patients, enabling shared EHR which will allow care professionals to create and update care plans for patients. http:// www. digitalhealth. net/ shared_ care_ records/ 47246/ berkshire-to-share-patient-records-with-graphnet
East London Genes and Health
A long-term study of 100 000 people of Bangladeshi and Pakistani origin, linking genomic data with EHR to study disease and treatments. http://www. genesandhealth. org/
Hospital Electronic Prescribing and Medicines Administration systems in Scotland
The implementation of e-prescribing and medicines administrations will enable improvements in care and in the secondary use of data for research. Comprehensive stakeholder analysis has led to early identification of barriers and facilitators to a learning health system approach. https://www. ncbi. nlm. nih. gov/ pubmed/ 28059691
Royal Free NHS Trust/Google DeepMind collaboration Artificial intelligence company, Google Deepmind and the Royal Free NHS Trust are working together on real-time EHR data to develop apps for use by health professional in the early detection of patient deterioration. http://www. bbc. co. uk/ news/ health-38055509
